Skip to main content

Table 5 Prophylactic anticoagulation in current pregnancy

From: Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan

 

AT deficiency n = 80

PC deficiency n = 50

PS deficiency n = 317

Total n = 447

Antepartum

Prophylactic anticoagulant therapy

42

30

175

247

Unfractionated heparin

(UFH) only

37

18

70

125

UFH combined with LDA※

3

12

104

119

Others#

2

0

1

3

No occurrence of thrombosis

38

28

174

240

Onset of thrombosis

4

2

1

7*

No prophylactic anticoagulant therapy

38

20

142

200

No occurrence of thrombosis

21

10

104

135

Occurrence of thrombosis

17

10

38

65**

Intrapartum

UFH only

19

11

43

73

Postpartum

Prophylactic anticoagulant therapy

72

35

166

273

UFH/low moleculer weight heparin (LMWH) only

17

12

93

122

UFH/LMWH combined with warfarin

46

18

62

126

Others§

9

5

11

25

No occurrence of thrombosis

71

34

166

271

Occurrence of thrombosis

1

1

0

2*

No prophylactic anticoagulant therapy

8

15

151

174

No occurrence of thrombosis

8

14

148

170

Occurrence of thrombosis

0

1

3$

4**

  1. AT Antithrombin, PC Protein C, PS Protein S. ※: In the antepartum period, there was significantly more frequent use of UFH combined with LDA both in women with PS deficiency (p < 0.0001) and PC deficiency (p < 0.01) than in women with AT deficiency. However, there was no significant difference in women with PS deficiency and PC deficiency. *: All of these 9 cases had a previous history and/or family history of thrombosis. **: Twenty-five of 69 cases had a previous history and/or family history of thrombosis. $: All of these 3 cases developed thrombosis after stopping postpartum prophylactic anticoagulant therapy. #: Others includes one case of warfarin and 2 cases of LMWH. §: Others includes 19 cases of warfarin only, 5 cases of DOAC and one case of UFH combined with LDA. The prophylactic anticoagulation used the most was 10,000 units/day of UFH. The dose of LDA was 80–100 mg/day and that of LMWH was 2000–4000 units/day. Although it is not an anticoagulant therapy, LDA alone without UFH was used in 90 cases (3 cases of AT deficiency, 6 cases of PC deficiency and 81 cases of PS deficiency) in the antepartum period